Zacks Investment Research
06 Jul 2026, 23:17 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Pacific Biosciences of California (PACB) currently holds a Zacks Rank of #2 (Buy). — A 'Buy' rating from a major research provider typically signals positive sentiment and potential for price appreciation.
+0.40PACB is projected to report an EPS of -$0.14 for the upcoming quarter, representing a 7.69% decrease year-over-year. — Declining earnings per share suggests weakening profitability or increased costs, which is a negative fundamental signal.
-0.30Consensus revenue estimates for PACB's upcoming quarter are $42.1 million, a 5.86% increase over the previous year. — Positive revenue growth indicates increasing demand for the company's genetic analysis technology despite losses.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
PACB shares have appreciated 15.86% over the past month, outperforming both the Medical sector and the S&P 500. — Strong short-term price momentum suggests growing investor confidence in the stock.
+0.20Which stocks this story touches
The company holds a Zacks Rank #2 (Buy) and has outperformed the S&P 500 over the past month, despite an anticipated EPS decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
